STOCK TITAN
  1. Home
  2. Sec-filings
  3. ROIV
  4. [Form 4] Roivant Sciences Ltd. Insider Trading Activity

Roivant officer exercises options, sells shares; 1,504,959 owned

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Roivant Sciences (ROIV) officer Eric Venker, President & Immunovant CEO, reported option exercises and open‑market sales. On 10/15–10/17/2025, he exercised 851,383 stock options at $15.85 and sold 851,383 common shares at weighted average prices of $16.93, $17.05, and $17.06, respectively. The transactions were executed under a Rule 10b5-1 trading plan adopted on March 28, 2025. Following these trades, he beneficially owns 1,504,959 common shares directly.

Positive

  • None.

Negative

  • None.
Insider Venker Eric
Role President & Immunovant CEO
Sold 851,383 shs ($14.47M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 118,418 $0.00 --
Exercise Common Shares 118,418 $15.85 $1.88M
Sale Common Shares 118,418 $17.06 $2.02M
Exercise Stock Option (Right to Buy) 318,282 $0.00 --
Exercise Common Shares 318,282 $15.85 $5.04M
Sale Common Shares 318,282 $17.05 $5.43M
Exercise Stock Option (Right to Buy) 414,683 $0.00 --
Exercise Common Shares 414,683 $15.85 $6.57M
Sale Common Shares 414,683 $16.93 $7.02M
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Shares — 1,623,377 shares (Direct)
Footnotes (1)
  1. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Venker Eric
(Last) (First) (Middle)
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY
(Street)
LONDON X0 SW1H 0DB
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President & Immunovant CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 10/15/2025 M 414,683 A $15.85 1,919,642 D
Common Shares 10/15/2025 S 414,683 D $16.93(1) 1,504,959 D
Common Shares 10/16/2025 M 318,282 A $15.85 1,823,241 D
Common Shares 10/16/2025 S 318,282 D $17.05(1) 1,504,959 D
Common Shares 10/17/2025 M 118,418 A $15.85 1,623,377 D
Common Shares 10/17/2025 S 118,418 D $17.06(1) 1,504,959 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $15.85 10/15/2025 M 414,683 (2) 03/31/2026 Common Stock 414,683 $0 436,700 D
Stock Option (Right to Buy) $15.85 10/16/2025 M 318,282 (2) 03/31/2026 Common Stock 318,282 $0 118,418 D
Stock Option (Right to Buy) $15.85 10/17/2025 M 118,418 (2) 03/31/2026 Common Stock 118,418 $0 0 D
Explanation of Responses:
1. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
2. Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ROIV’s officer report on Form 4?

He reported exercising 851,383 options at $15.85 and selling 851,383 common shares at weighted average prices on 10/15–10/17/2025.

Were the ROIV share sales under a 10b5-1 plan?

Yes. The filing states the sales were made under a Rule 10b5-1 plan adopted on March 28, 2025.

What were the sale prices disclosed for ROIV shares?

Weighted average prices were $16.93 on 10/15/2025, $17.05 on 10/16/2025, and $17.06 on 10/17/2025.

How many ROIV shares does the reporting person now own?

The filing shows 1,504,959 common shares beneficially owned directly after the reported transactions.

What positions does the reporting person hold at Roivant?

He is an officer, listed as President & Immunovant CEO.

What options were exercised in the ROIV Form 4?

Stock options with a $15.85 exercise price, fully vested from an award with a vesting commencement date of December 27, 2019.